Our multicenter international retrospective real-world clinical study demonstrated a significant improvement in RR in patients treated with P + CHT vs. P alone in a sample of European patients with stage IV NSCLC and high PD-L1 expression where RWE data were insufficient and, for example, due to different mutation rates, they could differ from other regions. Here, CD274 is linked to non-small cell lung carcinoma.